Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chronic Obstructive Pulmonary Disease
91%
COVID-19
79%
Indonesia
74%
Lung Function
73%
Asthma Patients
53%
Forced Vital Capacity
51%
Forced Expiratory Volume in 1 Second (FEV1)
50%
Mesenchymal Stem Cells
50%
Respiratory Symptoms
45%
Indonesian Patients
38%
Randomized Controlled Trial
38%
COVID-19 Pandemic
38%
Asthma Control
38%
Asthma
29%
Asthma Management
29%
Jakarta
26%
Safety Profile
24%
Vietnam
24%
Persistent Asthma
24%
Spirometry
23%
Adjuvant Therapy
23%
COVID-19 Patients
23%
Lung
22%
Chest X-ray
21%
Pathophysiology
21%
Regular Air
19%
Lung Function Parameters
19%
Bronchial Hyperresponsiveness
19%
CD11b+
19%
CD11c+ Cells
19%
Asthma-chronic Obstructive Pulmonary Disease Overlap Syndrome
19%
Lung Inflammation
19%
Allergic Airway Inflammation
19%
Nuclear Factor Erythroid 2-related Factor 2 (Nrf2)
19%
Syndecan-4
19%
Bronchiolar
19%
Observational Survey
19%
Lung Hyperinflation
19%
Heavy Metal Assessment
19%
Respirator
19%
Cement Dust Exposure
19%
Toll-like Receptor 9 (TLR9)
19%
OX40
19%
NKT Cells
19%
Patient Characteristics
19%
Human Umbilical Cord Mesenchymal Stromal Cells
19%
Emphysema
19%
Coliforms
19%
D-dimer
19%
Physician Perspective
19%
Medicine and Dentistry
Chronic Obstructive Pulmonary Disease
100%
Asthma
88%
COVID-19
77%
Mesenchymal Stem Cell
58%
Lung
57%
Forced Vital Capacity
54%
Cross Sectional Study
50%
Diseases
46%
Forced Expiratory Volume
35%
Primary Health Care
29%
Spirometry
26%
Adjuvant Therapy
22%
Patient with Asthma
20%
Prevalence
20%
Hyperbarism
19%
Patient Characteristics
19%
Syndecan 4
19%
Transcription Factor Nrf2
19%
Mental Health
19%
Emphysema
19%
Randomized Controlled Trial
19%
Lung Function
19%
Breathing
19%
Umbilical Cord
19%
Overlap Syndrome
19%
Pathophysiology
19%
Coronavirinae
19%
Allergic Rhinitis
19%
Heart Muscle Injury
19%
Diaphragm
19%
Asthma Exacerbation
19%
Gastroesophageal Reflux
19%
Supplementation
19%
Organophosphate
19%
Ciclonicate
19%
Long Term Exposure
19%
Clinician
19%
Echography
12%
Stem Cell
12%
Bronchodilating Agent
11%
Secretory Leukocyte Protease Inhibitor
11%
Patient Referral
9%
Sinusitis
9%
Edema
9%
N-Acetylprocainamide
9%
Prick Test
9%
Fenofibrate
9%
3-Amino-1,2,4-triazole
9%
Paranasal Sinus
9%
Survival Rate
8%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
96%
Diseases
61%
Chronic Obstructive Lung Disease
58%
Randomized Controlled Trial
38%
Syndrome
38%
Coronavirinae
38%
Inflammation
27%
Dimer
19%
Coughing
19%
Dyspnea
19%
Cytomegalovirus
19%
Dust Exposure
19%
Long Term Exposure
19%
Adjuvant
19%
Non Small Cell Lung Cancer
19%
Heart Muscle Injury
19%
D Dimer
19%
Placebo
19%
Ciclonicate
19%
Cognitive Defect
19%
Hyperbarism
19%
Allergic Rhinitis
19%
Interleukin 6
17%
Survival Rate
12%
Bronchodilating Agent
12%
Anti-Inflammatory Drug
12%
Adverse Event
11%
Comorbidity
9%
Provocation Test
9%
Cytokine Storm
9%
Amitrole
9%
Acecainide
9%
Fenofibrate
9%
Moroxydine
9%
Sinusitis
9%
Edema
9%
Cross-Sectional Study
9%
Organophosphate
7%
Degenerative Disease
7%
Adult Respiratory Distress Syndrome
6%
Fatality
6%
Diabetes Mellitus
6%
Table Salt
6%
Biological Marker
6%
Blood Clotting Disorder
6%
